The American College of Cardiology’s 73rd Annual Scientific Session & Expo (ACC24) took place over the weekend in Atlanta, spotlighting the latest and most impactful innovations in the field of cardiovascular care.
Tag Archive for: Boehringer Ingelheim
The German drugmaker said it planned to reduce its customer-facing teams in favor of a hybrid in-person and virtual sales model by June 30, in large part because pharmacy benefit managers (PBMs) had kept branded Humira on their lists of medicines for reimbursement.
The company stated it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, following a similar move by rival Boehringer Ingelheim earlier in the month.
The company said its new program will dramatically decrease costs at the pharmacy counter for patients, including those who are uninsured or underinsured.
Boehringer Ingelheim on Monday revealed new Phase II data for its investigational GLP-1/glucagon receptor dual agonist survodutide, showing that it could elicit significant improvements in patients with metabolic dysfunction-associated steatohepatitis.
Global animal health leader adopts Veeva Vault Clinical and Veeva Vault RIM for greater efficiency, visibility, and speed.
In a collaboration agreement announced today, Boehringer Ingelheim will gain access to Ribo’s platform to target hepatocytes with investigational siRNA therapies for non-alcoholic steatohepatitis.
Boehringer Ingelheim is striking a deal to leverage artificial intelligence for some of the hardest to treat cancers. Phenomic AI announced a collaboration agreement with the pharma giant Wednesday.
As the COVID-19 pandemic continues to recede, the top pharma companies intensified their focus into areas such as cancer and metabolic diseases to build up their pipelines, and their growth prospects, for the future.
Boehringer Ingelheim is concentrating on expanding its pipeline beyond Jardiance and other key products.